|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jacobs BL, Lee CT and Montie JE: Bladder
cancer in 2010: How far have we come? CA Cancer J Clin. 60:244–272.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin MD, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sujun H, Siwei Z, Wanqing C and Chang-Ling
L: Analysis of the status and trends of bladder cancer incidence in
China. Oncol Prog. 11:89–95. 2013.
|
|
5
|
Fleshner NE, Herr HW, Stewart AK, Murphy
GP, Mettlin C and Menck HR: The national cancer data base report on
bladder carcinoma. The American college of surgeons commission on
cancer and the american cancer society. Cancer. 78:1505–1513. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Richterstetter M, Wullich B, Amann K,
Haeberle L, Engehausen DG, Goebell PJ and Krause FS: The value of
extended transurethral resection of bladder tumour (TURBT) in the
treatment of bladder cancer. BJU Int. 110:E76–E79. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brausi M, Collette L, Kurth K, van der
Meijden AP, Oosterlinck W, Witjes JA, Newling D, Bouffioux C and
Sylvester RJ: EORTC Genito-Urinary Tract Cancer Collaborative
Group: Variability in the recurrence rate at first follow-up
cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of
the bladder: A combined analysis of seven EORTC studies. Eur Urol.
41:523–531. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmitz-Dräger BJ, Droller M, Lokeshwar
VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y,
Hemstreet GP, Malmstrom PU, et al: Molecular markers for bladder
cancer screening, early diagnosis and surveillance: The WHO/ICUD
consensus. Urol Int. 94:1–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goebell PJ, Groshen SL and Schmitz-Dräger
BJ: Guidelines for development of diagnostic markers in bladder
cancer. World J Urol. 26:5–11. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nicol TL, Kelly D, Reynolds L and
Rosenthal DL: Comparison of TriPath thin-layer technology with
conventional methods on non-gynecologic specimens. Acta Cytol.
444:567–575. 2000. View Article : Google Scholar
|
|
11
|
Bishop JW, Bigner SH, Colgan TJ, Husain M,
Howell LP, McIntosh KM, Taylor DA and Sadeghi MH: Multicenter
masked evaluation of AutoCyte PREP thin layers with matched
conventional smears. Including initial biopsy results. Acta Cytol.
42:189–197. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nasuti JF, Tam D and Gupta PK: Diagnostic
value of liquid based (ThinPrep) preparation in non-gynecologic
cases. Diagn Cytopathol. 24:137–141. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tisserand P, Fouquet C, Marck V, Mallard
C, Fabre M, Vielh P and Soussi T: Thinprep-processed fine-needle
samples of breast are effective material for RNA- and DNA-based
molecular diagnosis. Application to p53 mutation analysis. Cancer.
99:223–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Linder J: Recent advances in thin-layer
cytology. Diagn Cytopathol. 18:24–32. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weikert S, Christoph F, Schrader M, Krause
H, Miller K and Müller M: Quantitative analysis of survivin mRNA
expression in urine and tumour tissue of bladder cancer patients
and its potential relevance for disease detection and prognosis.
Int J Cancer. 116:100–104. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Horstmann M, Bontrup H, Hennenlotter J,
Taeger D, Weber A, Pesch B, Feil G, Patschan O, Johnen G, Stenzl A
and Brüning T: Clinical experience with survivin as a biomarker for
urothelial bladder cancer. World J Urol. 28:399–404. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adida C, Crotty PL, McGrath J, Berrebi D,
Diebold J and Altieri DC: Developmentally regulated expression of
the novel cancer anti-apoptosis gene survivin in human and mouse
differentiation. Am J Pathol. 152:43–49. 1998.PubMed/NCBI
|
|
18
|
Tanaka K, Iwamoto S, Gon G, Nohara T,
Iwamoto M and Tanigawa N: Expression of survivin and its
relationship to loss of apoptosis in breast carcinomas. Clin Cancer
Res. 6:127–134. 2000.PubMed/NCBI
|
|
19
|
Eissa S, Swellam M, Shehata H, El-Khouly
IM, El-Zayat T and El-Ahmady O: Expression of HYAL1 and survivin
RNA as diagnostic molecular markers for bladder cancer. J Urol.
183:493–498. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ku JH, Godoy G, Amiel GE and Lerner SP:
Urine survivin as a diagnostic biomarker for bladder cancer: A
systematic review. BJU Int. 110:630–636. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Smith SD, Wheeler MA, Plescia J, Colberg
JW, Weiss RM and Altieri DC: Urine detection of survivin and
diagnosis of bladder cancer. JAMA. 285:324–328. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang H, Xi X, Kong X, Huang G and Ge G:
The expression and significance of survivin mRNA in urinary bladder
carcinomas. J Cancer Res Clin Oncol. 130:487–490. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eble JN, Sauter G, Epstein JI and
Sesterhenn IA: World Health Organization Classification of
TumoursPathology and Genetics of Tumours of the Urinary System and
Male Genital Organs. IARC Press; Lyon: 2004
|
|
24
|
Sobin LH, Gospodariwicz M and Wittekind C:
International Union against Cancer: TNM classification of malignant
tumours2009, UICC international union against cancer. 7th edition.
Wiley-Blackwell; Hoboken, NJ: pp. 262–265. 2009
|
|
25
|
Gurley AM, Hidvegi DF, Bacus JW and Bacus
SS: Comparison of the papanicolaou and feulgen staining methods for
DNA quantification by image analysis. Cytometry. 11:468–474. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goodison S, Rosser CJ and Urquidi V:
Bladder cancer detection and monitoring: Assessment of urine- and
blood-based marker tests. Mol Diagn Ther. 17:71–84. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pina-Cabral L, Santos L, Mesquita B, Amaro
T, Magalhães S and Criado B: Detection of survivin mRNA in urine of
patients with superficial urothelial cell carcinomas. Clin Transl
Oncol. 9:731–736. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Srivastava AK, Singh PK, Srivastava K,
Singh D, Dalela D, Rath SK, Goel MM and Bhatt Brahma ML: Diagnostic
role of survivin in urinary bladder cancer. Asian Pac J Cancer
Prev. 14:81–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao J, Wang ZQ, Wang XY, Yang XJ and He
D: Preliminary study of diagnostic utility of molecular beacons in
bladder cancer. Urology. 76:512.e8–e13. 2010. View Article : Google Scholar
|
|
30
|
Chen HA, Su CM, Hsieh HY, Tung CL, Hsu CD,
Wang YH and Shen CH: Clinical significance of survivin expression
in patients with urothelial carcinoma. Dis Markers.
2014:5749852014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wiener HG, Mian C, Hiatel A, Pycha A,
Schatzl G and Marberger M: Can urine bound diagnostic tests replace
cystoscopy in the management of bladder cancer? J Urol.
159:1876–1880. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu DY, Nassar A and Siddiqui MT:
High-grade urothelial carcinoma: Comparison of SurePath
liquid-based processing with cytospin processing. Diagn Cytopathol.
37:16–20. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Koo JH, Lee HC, Song HG, Han HS, Lee KH,
Choe KH, Lee KM and Lee OJ: Comparison of cytologic evaluation
between conventional method and Cellprep PLUS liquid-based cytology
in body fluid. Korean J Pathol. 43:448–452. 2009. View Article : Google Scholar
|
|
34
|
Son SM, Koo JH, Choi SY, Lee HC, Lee YM,
Song HG, Hwang HK, Han HS, Yun SJ, Kim WJ, et al: Evaluation of
urine cytology in urothelial carcinoma patients: A comparison of
cellprepPlus® Liquid-Based cytology and conventional
smear. Korean J Pathol. 46:68–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nicol TL, Kelly D, Reynolds L and
Rosenthal DL: Comparison of TriPath thin-layer technology with
conventional methods on non-gynecologic specimens. Acta Cytol.
44:567–575. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fischler DF and Toddy SM: Nongynecologic
cytology utilizing the Thin-Prep Processor. Acta Cytol. 40:669–675.
1996. View Article : Google Scholar : PubMed/NCBI
|
